Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBT: 2020-2025

Historic EBT for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -$21.0 million.

  • Silence Therapeutics' EBT rose 40.96% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.2 million, marking a year-over-year increase of 15.15%. This contributed to the annual value of -$44.5 million for FY2024, which is 16.53% up from last year.
  • Silence Therapeutics' EBT amounted to -$21.0 million in Q3 2025, which was up 23.36% from -$27.3 million recorded in Q2 2025.
  • Silence Therapeutics' 5-year EBT high stood at $12.6 million for Q4 2024, and its period low was -$35.5 million during Q3 2024.
  • Moreover, its 3-year median value for EBT was -$18.6 million (2023), whereas its average is -$16.7 million.
  • In the last 5 years, Silence Therapeutics' EBT surged by 167.97% in 2024 and then slumped by 1,279.59% in 2025.
  • Silence Therapeutics' EBT (Quarterly) stood at -$15.1 million in 2021, then declined by 16.64% to -$17.7 million in 2022, then dropped by 5.23% to -$18.6 million in 2023, then skyrocketed by 167.97% to $12.6 million in 2024, then skyrocketed by 40.96% to -$21.0 million in 2025.
  • Its EBT was -$21.0 million in Q3 2025, compared to -$27.3 million in Q2 2025 and -$28.5 million in Q1 2025.